Quote | Atea Pharmaceuticals Inc. (NASDAQ:AVIR)
Last: | $3.91 |
---|---|
Change Percent: | 1.3% |
Open: | $3.84 |
Close: | $3.86 |
High: | $3.93 |
Low: | $3.7399 |
Volume: | 54,621 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
News | Atea Pharmaceuticals Inc. (NASDAQ:AVIR)
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
2024-05-22 17:10:41 ET Gainers: Chicken Soup for the Soul ( CSSEN ) +18% . Signature Bank ( OTC:SBNY ) +7% . PetMed Express ( PETS ) +6% . Prime Medicine ( PRME ) +6% . Sana Biotechnology ( SANA ) +5% . Losers: Cyto...
Message Board Posts | Atea Pharmaceuticals Inc. (NASDAQ:AVIR)
Subject | By | Source | When |
---|---|---|---|
Tang Capital makes_unsolicited $AVIR buyout offer@$5.75/sh +CVRa_55%_premium_to_ | DewDiligence | investorshub | 05/22/2023 3:14:19 PM |
Tang Capital makes_unsolicited $AVIR buyout offer@$5.75/sh +CVRa_55%_premium_to_Fridays_close: | DewDiligence | investorshub | 05/22/2023 2:54:56 PM |
Volume | Awl416 | investorshub | 05/22/2023 1:04:50 PM |
Price now last up | Docstemcell2020 | investorshub | 05/21/2023 10:32:28 AM |
Have a look at this | DewDiligence | investorshub | 05/19/2023 7:33:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...